N NN SVT

 A

5 KEY POINTS — Supraventricular Tachycardia in Newborns: 10-Year Multicentre Experience (Pasquinucci et al., 2026)

1. AV re-entrant tachycardia is the dominant mechanism
   Most neonatal SVT cases were due to atrioventricular re-entrant tachycardia (72%), with smaller proportions of AVNRT, PJRT, and focal atrial tachycardia.

2. Presentation is early and clinically significant
   Median onset occurred at ~14 days of life, and a notable proportion developed tachycardia-induced cardiomyopathy (28%), highlighting potential haemodynamic impact even in neonates.

3. Acute termination is usually achievable
   First-episode SVT was terminated by vagal manoeuvres (28%) or adenosine (47%), though some cases resolved spontaneously (13%), indicating generally good acute responsiveness.

4. Most infants require long-term therapy
   Nearly all patients (97%) needed maintenance antiarrhythmic treatment, typically for a prolonged period (median ~21 months), reflecting high recurrence risk.

5. Outcomes are generally good but management can be prolonged and complex
   Over ~3.75 years follow-up, recurrence after stopping therapy was uncommon, but some required electrophysiology studies and ablation, especially refractory cases. Biomarkers (e.g., NT-proBNP) and SVT subtype helped predict higher treatment burden.

A

This statement means that both blood test results and the specific electrical type of SVT can help identify which newborns are likely to have a more difficult or prolonged course of illness.

1. What is meant by “biomarkers (e.g., NT-proBNP)”?

• NT-proBNP (N-terminal pro–brain natriuretic peptide) is a hormone released by the heart when it is under strain or stress.

• In neonatal SVT, a high heart rate can reduce filling time and cardiac efficiency → the heart becomes “stretched” or stressed → NT-proBNP rises.

👉 So:

• Higher NT-proBNP = more cardiac stress

• This often correlates with:

  • poorer ventricular function

  • tachycardia-induced cardiomyopathy

  • need for more aggressive or prolonged treatment

---

2. What is meant by “SVT subtype”?

SVT is not one disease—it includes different electrical circuits:

• AV re-entrant tachycardia (AVRT) – most common, often accessory pathway (e.g., Wolff-Parkinson-White physiology)

• AV nodal re-entrant tachycardia (AVNRT) – less common in neonates

• Permanent junctional reciprocating tachycardia (PJRT) – often persistent and harder to control

• Focal atrial tachycardia – abnormal atrial focus firing

👉 Some types behave more aggressively than others:

• PJRT and focal atrial tachycardia tend to be:

  • more persistent

  • harder to terminate

  • more likely to recur

  • more likely to require multiple drugs or longer treatment

---

3. What does “predict higher treatment burden” mean in practice?

It means these factors are linked with:

• longer duration of antiarrhythmic therapy

• higher likelihood of combination therapy (more than one drug)

• increased need for ICU care or monitoring

• greater chance of recurrence after stopping treatment

• occasional need for electrophysiology study or ablation later in infancy

---

In simple terms

👉 If a newborn has:

• high NT-proBNP, and/or

• a more complex SVT type (like PJRT or focal atrial tachycardia),

they are more likely to have a tougher course requiring longer and more intensive treatment compared with simpler AVRT cases.

---

If you want, I can turn this into a one-line exam answer or viva response.